As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Abeona Therapeutics Inc. The largest reported stake is Nantahala Capital Management, LLC's, at 9.99%. 16 filings are on record since July 17, 2025 (Schedule 13G/A, May 15, 2026).
Who owns Abeona Therapeutics Inc.?
Sell to companies like Abeona Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: James Russell Revocable Trust · Sole voting: 0 · Shared voting: 3,479,963 · Sole dispositive: 0 · Shared dispositive: 3,479,963 · SCHEDULE 13D, 2026-10-23
- · Reporting person: Montanova Capital, LLC · Sole voting: 0 · Shared voting: 500,000 · Sole dispositive: 0 · Shared dispositive: 500,000 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Nantahala Capital Partners Limited Partnership · Percent: 5.82% · SCHEDULE 13G/A
- · Holder: Nantahala Capital Management, LLC · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Orin Hirschman · Percent: 5.4% · SCHEDULE 13G
Abeona Therapeutics Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-17. 7 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 9.99% | 5,775,350 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| James Russell Revocable Trust | 6.1% | 3,479,963 | SCHEDULE 13D, 2026-10-23 | 2026-10-15 |
| Nantahala Capital Partners Limited Partnership | 5.82% | 3,333,757 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.8% | 2,949,262 | SCHEDULE 13G, 2025-07-17 | 2025-06-30 |
| 5.4% | 3,100,000 | SCHEDULE 13G, 2026-04-28 | 2026-03-31 | |
| Funicular Funds, LP | 5.3% | 3,007,329 | SCHEDULE 13G, 2026-04-06 | 2026-03-27 |
| 5.16% | 2,943,629 | SCHEDULE 13G, 2026-03-27 | 2026-03-26 | |
| Montanova Capital, LLC | 0.9% | 500,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Adage Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
Holding shares or following this stake? See who's behind Abeona Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Abeona Therapeutics Inc. and the records around it.
Abeona Therapeutics Inc. elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Daniel Kaufman also filed stake reports on 6 other companies: AUNA S.A. (May 2026), DELCATH SYSTEMS, INC. (Mar 2026), i-80 Gold Corp. (Jan 2026)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), KIORA PHARMACEUTICALS, INC. (May 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
Watch Abeona Therapeutics Inc.
Get an email when Abeona Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Abeona Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Abeona Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abeona Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| James Russell Revocable Trust | 0 | 3,479,963 | 0 | 3,479,963 | SCHEDULE 13D, 2026-10-23 |
| James Russell | 0 | 3,479,963 | 0 | 3,479,963 | SCHEDULE 13D, 2026-10-23 |
| Montanova Capital, LLC | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G/A, 2026-08-14 |
| Aaron Cowen | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Abeona Therapeutics Inc. by CUSIP 00289Y206 and gives its principal executive office as 6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH 44103 (SCHEDULE 13D, 2026-10-23).
Source of funds (Item 3)
The Shares reported herein were acquired with personal funds of the Trust for an aggregate purchase price of approximately $17,776,513.00 (excluding brokerage commissions). An additional 759,088 Shares acquired since the Schedule 13G were acquired for approximately $3,671,466.00. No borrowed funds were used.James Russell Revocable Trust, SCHEDULE 13D, 2026-10-23
Purpose of Transaction (Item 4)
James Russell Revocable Trust
The Reporting Persons originally acquired the Shares for investment purposes and reported their beneficial ownership on Schedule 13G. Over time, based on their review of the Issuer's public filings, press releases and other public communications, the Reporting Persons became concerned regarding the Issuer's operational execution, the consistency of management's public statements with subsequent operating results, and the Issuer's governance. Beginning in May 2026, the Reporting Persons communicated their concerns (as a shareholder in an informal manner), to the Issuer's management and board of directors (the "Board"). On October 14, 2026, Mr. Russell met electronically with two members of the Board: Faith L. Charles, Interim Chair of the Board and Chair of the Board's Nominating and Corporate Governance Committee, and Keith A. Goldan, Chair of the Board's Audit Committee. At that meeting, Mr. Russell presented a summary of his concerns, including the Board should consider adding additional independent directors, and expressed his view that a change in the Issuer's executive leadership should be explored. Mr. Russell also requested a written response from the Board. On October 15, 2026, Ms. Charles advised Mr. Russell that each of the concerns discussed have been shared with the full Board and should any action be taken, communications when released by the Issuer should be reviewed versus directly to him. The Reporting Persons intend to continue to engage with the …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.8% | SCHEDULE 13G |
| 2025-08-13 | Suvretta Capital Management, LLC | 5.2% | SCHEDULE 13G/A |
| 2025-09-30 | James Russell Revocable Trust | 5.3% | SCHEDULE 13G |
| 2025-10-06 | Nantahala Capital Partners Limited Partnership | 5.09% | SCHEDULE 13G |
| 2025-10-06 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 5.07% | SCHEDULE 13G |
| 2025-11-13 | Adage Capital Management, L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-02-12 | Adage Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-27 | Daniel Kaufman | 5.16% | SCHEDULE 13G |
| 2026-04-06 | Funicular Funds, LP | 5.3% | SCHEDULE 13G |
| 2026-04-28 | Orin Hirschman | 5.4% | SCHEDULE 13G |
| 2026-05-15 | Nantahala Capital Partners Limited Partnership | 5.82% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Montanova Capital, LLC | 0.9% | SCHEDULE 13G/A |
| 2026-10-23 | James Russell Revocable Trust | 6.1% | SCHEDULE 13D |
Questions about who owns Abeona Therapeutics Inc.
Who owns Abeona Therapeutics Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Abeona Therapeutics Inc.: Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-05-15), James Russell Revocable Trust (6.1%, Schedule 13D, filed 2026-10-23), Nantahala Capital Partners Limited Partnership (5.82%, Schedule 13G/A, filed 2026-05-15), BlackRock, Inc. (5.8%, Schedule 13G, filed 2025-07-17) and Orin Hirschman (5.4%, Schedule 13G, filed 2026-04-28); 2 more are listed above.
Who are the largest shareholders of Abeona Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Abeona Therapeutics Inc. on this page are Nantahala Capital Management, LLC (9.99%), James Russell Revocable Trust (6.1%) and Nantahala Capital Partners Limited Partnership (5.82%).
When did Nantahala Capital Management, LLC buy into Abeona Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nantahala Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-10-06, reporting 9.99%; its latest, Schedule 13G/A filed 2026-05-15, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Abeona Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 12, 2026 | Leadership change: Michael Amoroso departs, Director, and 1 more | — | Leadership changes | Source |
| April 7, 2026 | Leadership change: Keith A. Goldan appointed, Director, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Abeona Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.